60 Degrees Net Income Over Time
| SXTP Stock | 3.95 0.10 2.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out 60 Degrees Performance and 60 Degrees Correlation. Can Pharmaceuticals industry sustain growth momentum? Does SXTP have expansion opportunities? Factors like these will boost the valuation of 60 Degrees. If investors know SXTP will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating 60 Degrees demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (3.10) | Revenue Per Share | Quarterly Revenue Growth 2.569 | Return On Assets | Return On Equity |
The market value of 60 Degrees Pharmaceu is measured differently than its book value, which is the value of SXTP that is recorded on the company's balance sheet. Investors also form their own opinion of 60 Degrees' value that differs from its market value or its book value, called intrinsic value, which is 60 Degrees' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because 60 Degrees' market value can be influenced by many factors that don't directly affect 60 Degrees' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 60 Degrees' value and its price as these two are different measures arrived at by different means. Investors typically determine if 60 Degrees is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, 60 Degrees' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare 60 Degrees Pharmaceu and related stocks such as CNS Pharmaceuticals, Calidi Biotherapeutics, and Silo Pharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNSP | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (7.4 M) | (3.9 M) | (9.5 M) | (14.5 M) | (15.3 M) | (18.9 M) | (14.9 M) | (13.4 M) | (14 M) |
| CLDI | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (10.9 M) | (25.4 M) | (29.2 M) | (22.1 M) | (19.9 M) | (20.9 M) |
| CANF | (3.7 M) | (6.7 M) | (5.6 M) | (8.3 M) | (6.1 M) | (4.8 M) | (6.9 M) | (5 M) | (6.6 M) | (12.6 M) | (14.4 M) | (12.6 M) | (10.2 M) | (7.6 M) | (7.9 M) | (7.1 M) | (7.4 M) |
| CMND | (33.2 K) | (33.2 K) | (33.2 K) | (33.2 K) | (46.9 K) | (24.2 K) | (6.5 K) | (194.5 K) | (105.3 K) | (233.2 K) | (3.7 M) | (9.9 M) | (11.9 M) | (7.3 M) | (5.4 M) | (4.9 M) | (5.1 M) |
| KZIA | (17.1 M) | 1.3 M | (1 M) | (7.5 M) | (7.1 M) | (12.1 M) | (10.7 M) | (6 M) | (10.3 M) | (12.5 M) | (8.4 M) | (25 M) | (20.5 M) | (26.8 M) | (20.7 M) | (23.8 M) | (25 M) |
| JAGX | (25.5 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (16.3 M) | (14.7 M) | (22 M) | (32.1 M) | (38.5 M) | (33.8 M) | (52.6 M) | (47.5 M) | (41.3 M) | (38.5 M) | (34.6 M) | (36.4 M) |
| SNGX | (1.2 M) | (2.4 M) | (4.2 M) | (10.1 M) | (6.7 M) | (7.8 M) | (3.2 M) | (7.1 M) | (8.9 M) | (9.4 M) | (17.7 M) | (12.6 M) | (13.8 M) | (6.1 M) | (8.3 M) | (7.4 M) | (7.8 M) |
| BDRX | (4 M) | (4 M) | (4 M) | (4.1 M) | (8.8 M) | (10.1 M) | (6.2 M) | (11.7 M) | (10.4 M) | (10.1 M) | (22.2 M) | (5.5 M) | (7.7 M) | (7.1 M) | (5.7 M) | (5.2 M) | (5.4 M) |
60 Degrees Pharmaceu and related stocks such as CNS Pharmaceuticals, Calidi Biotherapeutics, and Silo Pharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in 60 Degrees Pharmaceu financial statement analysis. It represents the amount of money remaining after all of 60 Degrees Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| 60 Degrees Pharmaceuticals | SXTP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1025 Connecticut Avenue |
| Exchange | NASDAQ Exchange |
null 3.95
Additional Tools for SXTP Stock Analysis
When running 60 Degrees' price analysis, check to measure 60 Degrees' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 60 Degrees is operating at the current time. Most of 60 Degrees' value examination focuses on studying past and present price action to predict the probability of 60 Degrees' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 60 Degrees' price. Additionally, you may evaluate how the addition of 60 Degrees to your portfolios can decrease your overall portfolio volatility.